ENOV — Stock Film
STOCK FILMSCENE 1/11ENOV · $26.10
Stock Expert AI presents
ENOV
Enovis Corporation
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Enovis Corporation. A quick introduction.

On the stock market since 2008, it operates in the world of health and science. It has 7,802 employees. Now — the numbers.

on the stock market since 2008
7,802 employees
$1.5B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.5.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
63%Fabrication Technology
Fabrication Technology 63%Medical Technology 37%
63% of all revenue comes from a single line: Fabrication Technology.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $1.4B
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
52
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
51
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
68
strong

Clearly above the class average — a step short of the very top.

GROWTH
66
strong

Clearly above the class average — a step short of the very top.

PRICE MOMENTUM
50
average

The price is looking for direction — no strong breakout, no collapse.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 13% a year on average.

2
THE BRIGHT SIDE · 2/3
Sales are holding up

The company sells $2.2B a year; the problem isn’t sales — it’s costs running above that number.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/2
The losses continue

A loss of $1.2B against $2.2B in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, ENOV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ENOV has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film